内分泌指南

订阅

MedSci主页 / 所有栏目 / 内分泌指南

2021 ESA立场声明：成人原发性甲状旁腺功能亢进的评估和药物治疗

2021-12-21 澳大利亚内分泌学会 Clin Endocrinol (Oxf)

甲状腺原发性甲状旁腺功能亢进

2021年12月，澳大利亚内分泌学会(ESA)联合澳大利亚&新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的评估和药物治疗共识声明。

中文标题：

2021 ESA立场声明：成人原发性甲状旁腺功能亢进的评估和药物治疗

英文标题：

Primary hyperparathyroidism in adults-(Part I) assessment and medical management

发布机构：

澳大利亚内分泌学会

发布日期：

2021-12-21

简要介绍：

2021年12月，澳大利亚内分泌学会(ESA)联合澳大利亚&新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的评估和药物治疗共识声明。本文主要针对成人原发性甲状旁腺功能亢进的评估和药物治疗提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ESA立场声明：成人原发性甲状旁腺功能亢进的评估和药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=ca1951c0022993c8, title=2021 ESA立场声明：成人原发性甲状旁腺功能亢进的评估和药物治疗, enTitle=Primary hyperparathyroidism in adults-(Part I) assessment and medical management, guiderFrom=Clin Endocrinol (Oxf), authorId=0, author=, summary=2021年12月，澳大利亚内分泌学会(ESA)联合澳大利亚&新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的评估和药物治疗共识声明。, cover=https://img.medsci.cn/20211222/1640183099383_1608702.png, journalId=0, articlesId=null, associationId=1266, associationName=澳大利亚内分泌学会, associationIntro=, copyright=0, guiderPublishedTime=Tue Dec 21 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年12月，澳大利亚内分泌学会(ESA)联合澳大利亚&amp;新西兰内分泌外科医生协会以及骨矿学会共同发布了成人原发性甲状旁腺功能亢进的评估和药物治疗共识声明。本文主要针对成人原发性甲状旁腺功能亢进的评估和药物治疗提供指导建议。</span></p>, tagList=[TagDto(tagId=736, tagName=甲状腺), TagDto(tagId=100875, tagName=原发性甲状旁腺功能亢进)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=100875, guiderKeyword=原发性甲状旁腺功能亢进, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2515, appHits=112, showAppHits=0, pcHits=302, showPcHits=2402, likes=0, shares=9, comments=7, approvalStatus=1, publishedTime=Wed Dec 22 22:23:36 CST 2021, publishedTimeString=2021-12-21, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Wed Dec 22 22:30:32 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 00:53:55 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ESA立场声明：成人原发性甲状旁腺功能亢进的评估和药物治疗.pdf)])
2021 ESA立场声明：成人原发性甲状旁腺功能亢进的评估和药物治疗.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2095936, encodeId=26d5209593640, content=感谢，一直没找到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=88fd6570840, createdName=ms9000000065457075, createdTime=Mon Oct 24 23:08:38 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238166, encodeId=726e12381667b, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67378272776, createdName=ms3000000055567753, createdTime=Thu Aug 11 23:26:45 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185441, encodeId=87fe11854419d, content=👍👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:35:38 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179604, encodeId=ef3a11e960416, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:18 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179603, encodeId=b19511e960388, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:10 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-10-24 ms9000000065457075

    感谢，一直没找到

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2095936, encodeId=26d5209593640, content=感谢，一直没找到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=88fd6570840, createdName=ms9000000065457075, createdTime=Mon Oct 24 23:08:38 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238166, encodeId=726e12381667b, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67378272776, createdName=ms3000000055567753, createdTime=Thu Aug 11 23:26:45 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185441, encodeId=87fe11854419d, content=👍👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:35:38 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179604, encodeId=ef3a11e960416, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:18 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179603, encodeId=b19511e960388, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:10 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-08-11 ms3000000055567753

    非常棒

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2095936, encodeId=26d5209593640, content=感谢，一直没找到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=88fd6570840, createdName=ms9000000065457075, createdTime=Mon Oct 24 23:08:38 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238166, encodeId=726e12381667b, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67378272776, createdName=ms3000000055567753, createdTime=Thu Aug 11 23:26:45 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185441, encodeId=87fe11854419d, content=👍👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:35:38 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179604, encodeId=ef3a11e960416, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:18 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179603, encodeId=b19511e960388, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:10 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-18 ms6000000807686529

    👍👍👍👍

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2095936, encodeId=26d5209593640, content=感谢，一直没找到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=88fd6570840, createdName=ms9000000065457075, createdTime=Mon Oct 24 23:08:38 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238166, encodeId=726e12381667b, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67378272776, createdName=ms3000000055567753, createdTime=Thu Aug 11 23:26:45 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185441, encodeId=87fe11854419d, content=👍👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:35:38 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179604, encodeId=ef3a11e960416, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:18 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179603, encodeId=b19511e960388, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:10 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-01 一己怀

    非常实用，谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2095936, encodeId=26d5209593640, content=感谢，一直没找到, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=88fd6570840, createdName=ms9000000065457075, createdTime=Mon Oct 24 23:08:38 CST 2022, time=2022-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238166, encodeId=726e12381667b, content=非常棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67378272776, createdName=ms3000000055567753, createdTime=Thu Aug 11 23:26:45 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185441, encodeId=87fe11854419d, content=👍👍👍👍, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:35:38 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179604, encodeId=ef3a11e960416, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:18 CST 2022, time=2022-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179603, encodeId=b19511e960388, content=好东西，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:05:10 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
    2022-01-01 一己怀

    好东西，谢谢

    0

相关指南

2021 ESA立场声明：成人原发性甲状旁腺功能亢进的手术治疗和术后随访

澳大利亚内分泌学会(ESA,Endocrine Society of Australia) · 2021-12-19

桥本氏甲状腺炎中西医结合质量控制指标体系北京专家共识（2021版）

北京中西医结合学会甲状腺病专业委员会 · 2021-12-10

《2020～2021年欧洲内分泌参考网共识指南：先天性甲状腺功能减低症》解读

暂未更新 · 2021-11-15

《2020～2021 年欧洲内分泌参考网共识指南：先天性甲状腺功能减低症》解读

暂未更新 · 2021-11-10

甲状腺肿瘤患者样本采集、处理、储存和 信息采集规范

中国医药生物技术协会 · 2021-10-01

2021 DAS/BAETS/ENTUK共识指南：甲状腺术后血肿的管理

困难气道协会(DAS,Difficult Airway Society) · 2021-09-21

拓展阅读

2016 AAES指南：原发性甲状旁腺功能亢进的管理

美国内分泌外科协会(AAES,American Association of Endocrine Surgeons) · 2016-08-10

原发性甲状旁腺功能亢进热消融治疗专家共识

白求恩精神研究会内分泌和糖尿病学分会介入内分泌专业委员会(学组) · 2021-10-14

2021 ESA立场声明：成人原发性甲状旁腺功能亢进的手术治疗和术后随访

澳大利亚内分泌学会(ESA,Endocrine Society of Australia) · 2021-12-19